News

Evommune starts second midstage clinical trial this year
Evommune launches mid-stage trials for immune-modulating drugs targeting skin conditions, backed by $115M funding and led by ...
PipelineReview.com7d
Evommune Initiates Phase 2b Trial of MRGPRX2 Antagonist, EVO756, in Adults with Moderate to Severe Chronic Spontaneous Urticaria
PALO ALTO, CA, USA I April 15, 2025 I Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated ...
WDAF-TV7d
Evommune Initiates Phase 2b Trial of MRGPRX2 Antagonist, EVO756, in Adults with Moderate to Severe Chronic Spontaneous Urticaria
Novel mechanism of action (MOA) inhibits MRGPRX2 on both mast cells and peripheral sensory neurons - a key differentiator to other therapeutic options Potential first- and best-in-class safety and ...
WGN Radio7d
Evommune Initiates Phase 2b Trial of MRGPRX2 Antagonist, EVO756, in Adults with Moderate to Severe Chronic Spontaneous Urticaria
Novel mechanism of action (MOA) inhibits MRGPRX2 on both mast cells and peripheral sensory neurons - a key differentiator to other therapeutic options Potential first- and best-in-class safety and ...